C. E. Allen, S. Ladisch, and K. L. Mcclain, How I treat Langerhans cell histiocytosis, Blood, vol.126, pp.26-35, 2015.

G. Badalian-very, J. Vergilio, B. A. Degar, L. E. Macconaill, B. Brandner et al., Recurrent BRAF mutations in Langerhans cell histiocytosis, Blood, vol.116, pp.1919-1923, 2010.

M. Berres, K. P. Lim, T. Peters, J. Price, H. Takizawa et al., BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups, The Journal of Experimental Medicine, vol.211, pp.669-683, 2014.

A. N. Butt and R. Swaminathan, Overview of circulating nucleic acids in plasma/serum, Annals of the New York Academy of Sciences, vol.1137, pp.236-242, 2008.

C. Tsao, S. Weiss, J. Hudson, C. Christophi, C. Cebon et al., Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations, Scientific Reports, vol.5, p.11198, 2015.

S. Dawson, D. W. Tsui, M. Murtaza, H. Biggs, O. M. Rueda et al., Analysis of circulating tumor DNA to monitor metastatic breast cancer, New England Journal of Medicine, vol.368, pp.1199-1209, 2013.

L. A. Diaz and A. Bardelli, Liquid biopsies: genotyping circulating tumor DNA, Journal of Clinical Oncology, vol.32, pp.579-586, 2014.

J. Donadieu, C. Piguet, F. Bernard, M. Barkaoui, M. Ouache et al., A new clinical score for disease activity in Langerhans cell histiocytosis, Pediatric Blood & Cancer, vol.43, pp.770-776, 2004.

J. Donadieu, F. Bernard, M. Van-noesel, M. Barkaoui, O. Bardet et al., Salvage Group of the Histiocyte Society. (2015) Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study, Blood, vol.126, pp.1415-1423

R. M. Egeler, A. G. Van-halteren, P. C. Hogendoorn, J. D. Laman, and P. J. Leenen, Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage, Immunological Reviews, vol.234, pp.213-232, 2010.

H. Gadner, N. Grois, U. P?-otschger, M. Minkov, M. Aric-o et al., Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification, Blood, vol.111, pp.2556-2562, 2008.

H. Gadner, M. Minkov, N. Grois, U. P?-otschger, E. Thiem et al., Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis, Blood, vol.121, pp.5006-5014, 2013.

M. Girschikofsky, M. Arico, D. Castillo, A. Chu, C. Doberauer et al., Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net, Orphanet Journal of Rare Diseases, vol.8, p.72, 2013.

A. Guyot-goubin, J. Donadieu, M. Barkaoui, S. Bellec, C. Thomas et al., Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, Pediatric Blood & Cancer, vol.51, pp.71-75, 2000.
URL : https://hal.archives-ouvertes.fr/inserm-00255977

R. Haupt, M. Minkov, I. Astigarraga, E. Sch?-afer, V. Nanduri et al., Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years, Pediatric Blood & Cancer, vol.60, pp.175-184, 2013.

S. H-eritier, M. Jehanne, G. Leverger, J. Emile, J. Alvarez et al., Vemurafenib use in an infant for high-risk langerhans cell histiocytosis, JAMA Oncology, vol.1, pp.836-838, 2015.

S. H-eritier, J. Emile, M. Barkaoui, C. Thomas, S. Fraitag et al., BRAF mutation correlates with high-risk langerhans cell histiocytosis and, Journal of Clinical Oncology, vol.34, pp.3023-3030, 2016.

D. M. Hyman, E. L. Diamond, C. R. Vibat, L. Hassaine, J. C. Poole et al., Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders, Cancer Discovery, vol.5, pp.64-71, 2015.

F. Janku, C. R. Vibat, K. Kosco, V. R. Holley, G. Cabrilo et al., BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease, Oncotarget, vol.5, pp.3607-3610, 2014.

C. Jovelet, E. Ileana, M. Le-deley, N. Motte, S. Rosellini et al., Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOS-CATO trial, Clinical Cancer Research, vol.22, pp.2960-2968, 2016.

K. Jung, M. Fleischhacker, and A. Rabien, Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature, Clinica Chimica Acta, vol.411, pp.1611-1624, 2010.

M. Kobayashi and A. Tojo, The BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis, Blood, vol.124, pp.2610-2611, 2014.

C. Rigaud, M. A. Barkaoui, C. Thomas, Y. Bertrand, A. Lambilliotte et al., Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age, British Journal of Haematology, vol.174, pp.887-898, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01331987

H. Schwarzenbach, D. S. Hoon, and K. Pantel, Cell-free nucleic acids as biomarkers in cancer patients, Nature Reviews Cancer, vol.11, pp.426-437, 2011.

V. Taly, D. Pekin, L. Benhaim, S. K. Kotsopoulos, D. L. Corre et al., Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clinical Chemistry, vol.59, pp.1722-1731, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299581

A. R. Thierry, F. Mouliere, S. El-messaoudi, C. Mollevi, E. Lopez-crapez et al., Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nature Medicine, vol.20, pp.430-435, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02168071